Impact of CREB-driven mechanism in shaping the tumor-immune landscape
CREB 驱动机制对塑造肿瘤免疫景观的影响
基本信息
- 批准号:10586923
- 负责人:
- 金额:$ 32.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-01-01 至 2027-12-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAutomobile DrivingBindingBiological Response ModifiersCD8-Positive T-LymphocytesCRISPR/Cas technologyCell LineCellsChemotaxisClinicalComplementComplexCyclic AMP-Responsive DNA-Binding ProteinDataDevelopmentDiseaseFibrosisGeneticGenetic ModelsGenetic TranscriptionGenetically Engineered MouseHigh-Throughput Nucleotide SequencingHumanImmuneImmune checkpoint inhibitorImmunophenotypingImmunosuppressionImmunotherapeutic agentImmunotherapyImpairmentInfiltrationInflammationInterleukin-6KRAS2 geneKnock-outLIF geneLaboratoriesMacrophageMalignant NeoplasmsMalignant neoplasm of pancreasMediatingMediatorModelingMolecularMusMyelogenousMyeloid-derived suppressor cellsNatureNeoplasm MetastasisNeoplasmsOncogenicOrganoidsPancreasPancreatic Ductal AdenocarcinomaPathway interactionsPatientsPhenotypePrimary NeoplasmProductionPrognosisReceptor SignalingRegulationRegulatory T-LymphocyteResistanceRoleSTAT3 geneSafetySamplingShapesSignal TransductionT-Cell ActivationT-LymphocyteTherapeuticTimeTissuesTumor BurdenTumor PromotionTumor-associated macrophagesUp-RegulationWorkadaptive immune responseanti-tumor immune responseattenuationcell growthcheckpoint inhibitioncheckpoint therapychemotherapeutic agentclinically relevantcytokineeffective therapygene regulatory networkgenome editinghumanized mouseimmunomodulatory therapiesimmunoregulationimprovedin vivoinhibitorinsightleukemia inhibitory factor receptormortalitymouse modelneoplastic cellnovel therapeutic interventionpancreatic ductal adenocarcinoma modelpancreatic neoplasmparacrinepatient derived xenograft modelpharmacologicpre-clinicalpreclinical studypromoterrecruitrelease factorresponsesynergismtherapy resistanttranscription factortranscription regulatory networktreatment strategytumortumor growthtumor microenvironmenttumor-immune system interactionstumorigenesis
项目摘要
PROJECT SUMMARY
Pancreatic ductal adenocarcinoma (PDAC) is characterized by resistance to current therapies, a high degree of
desmoplasia, and an immunosuppressive tumor microenvironment (TME). This scientific proposal focuses on
cyclic AMP Response Element Binding protein 1 (CREB) as a transcriptional factor downstream of KRAS that
promotes disease aggressiveness and poor survival. Genetic loss or pharmacological inhibition of CREB leads
to significant attenuation of PDAC tumor burden and improved survival in multiple murine PDAC models. Utilizing
high throughput sequencing approaches, we have identified tumor cell-derived leukemia inhibitory factor (LIF)
as a key CREB-regulated immunomodulatory cytokine, serving as a possible paracrine mediator of tumor-
macrophage crosstalk in the TME. We hypothesize that targeting the CREB-LIF signaling axis can remodel the
immunosuppressive TME by significantly impacting tumor-associated macrophages (TAM)s and reinvigorating
the T cell-based adaptive anti-tumor immune response to improve the efficacy of checkpoint immunotherapy.
Based on our preliminary data, the critical role of the CREB regulated LIF signaling will be investigated through
three specific aims. 1) Elucidate the molecular mechanism and impact of CREB regulated LIF in PDAC
oncogenesis. Here, we will assess the CREB-mediated regulation and functional roles of tumor cell-derived LIF
by exploring the nucleo-cytoplasmic localization, interaction with transcriptional complexes, and gene regulatory
networks. We identify the CREB-LIF axis requirement in the tumor cell growth using CRISPR/Cas9 genome
editing with CREB on or off in vivo pancreas tissues and evaluate the expression of LIF relative to CREB in
patient PDAC tissues, patient-derived xenografts, and primary tumor derivative organoids. 2) Determine how
CREB-dependent LIFR signaling in macrophages impacts the tumor immune landscape. We hypothesize that
the CREB modulates LIF release and promotes TAM infiltration/polarization towards a tumor-promoting M2-like
phenotype via activating STAT3 in macrophages. We will determine the effect of CREB-regulated LIF release
on TAM activity using CREB on or off with LIF knockout tumor cells and assess the impact of CREB-regulated
LIF signaling on the adaptive immune response and TME during PDAC progression in myeloid-specific knockout
models of Lifr and Stat3, and 3) Determine if CREB inhibition and conventional immunotherapeutic approaches
reduce tumor growth and improve overall survival. We hypothesize that the tumor cell-intrinsic CREB-LIF
activation is a pivotal switch that drives immune suppression in the pancreatic TME, which can synergize with
immune checkpoint inhibition. We will use CREB inhibitor with checkpoint inhibitor to establish the safety of the
therapies and study tumor growth and overall survival in genetic mouse models, patient-derived xenografts, and
organoids to further complement these preclinical studies. Together, these results will provide new therapeutic
strategies to reduce mortality from this disease. Furthermore, these studies can be broadly applicable to the
myriad of other malignancies where CREB-LIF signaling is altered.
项目摘要
胰腺导管腺癌(PDAC)的特征在于对当前疗法的抗性,高度的肿瘤坏死,以及高水平的肿瘤转移。
结缔组织增生和免疫抑制性肿瘤微环境(TME)。这项科学建议的重点是
环AMP反应元件结合蛋白1(CREB)作为KRAS下游的转录因子,
促进了疾病的侵袭性和生存率的下降。CREB导联的遗传丢失或药物抑制
在多种鼠PDAC模型中显著减轻PDAC肿瘤负荷并提高存活率。利用
高通量测序方法,我们已经确定了肿瘤细胞衍生的白血病抑制因子(LIF)
作为一个关键的CREB调节的免疫调节细胞因子,作为一个可能的旁分泌介导的肿瘤,
TME中的巨噬细胞串扰。我们假设,靶向CREB-LIF信号传导轴可以重塑
免疫抑制性TME通过显著影响肿瘤相关巨噬细胞(TAM)和重新激活
基于T细胞的适应性抗肿瘤免疫应答,以提高检查点免疫疗法的疗效。
基于我们的初步数据,CREB调节的LIF信号转导的关键作用将通过以下方式进行研究:
三个具体目标。1)阐明CREB调控LIF在PDAC中的分子机制及其影响
肿瘤发生在这里,我们将评估CREB介导的调节和肿瘤细胞衍生的LIF的功能作用,
通过探索核质定位,与转录复合物的相互作用,以及基因调控,
网络.我们使用CRISPR/Cas9基因组鉴定了肿瘤细胞生长中CREB-LIF轴的需求
用CREB在体内胰腺组织上或在体内胰腺组织上进行编辑,并评估LIF相对于CREB在胰腺组织中的表达。
患者PDAC组织、患者来源的异种移植物和原发性肿瘤衍生类器官。2)确定如何
巨噬细胞中的CREB依赖性LIFR信号传导影响肿瘤免疫景观。我们假设
CREB调节LIF释放并促进TAM向促肿瘤M2样细胞浸润/极化,
表型通过激活巨噬细胞中的STAT 3来表达。我们将确定CREB调节的LIF释放的影响,
用LIF敲除肿瘤细胞使用CREB开启或关闭对TAM活性的影响,并评估CREB调节的TAM活性的影响。
骨髓特异性基因敲除PDAC进展过程中LIF信号对适应性免疫应答和TME的影响
Lifr和Stat 3的模型,以及3)确定CREB抑制和常规免疫抑制方法是否
减少肿瘤生长并提高总体存活率。我们假设肿瘤细胞内源性CREB-LIF
激活是驱动胰腺TME中免疫抑制的关键开关,其可以与
免疫检查点抑制。我们将使用CREB抑制剂和检查点抑制剂来确定
在遗传小鼠模型、患者来源的异种移植物中研究肿瘤生长和总生存期,
类器官以进一步补充这些临床前研究。总之,这些结果将提供新的治疗方法,
降低这种疾病死亡率的战略。此外,这些研究可广泛适用于
CREB-LIF信号传导被改变的无数其他恶性肿瘤。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nagaraj S. Nagathihalli其他文献
Altered SignaLing Pathways and Potential Therapeutic Targets in Pancreatic Cancer
胰腺癌信号通路的改变和潜在的治疗靶点
- DOI:
- 发表时间:
2014 - 期刊:
- 影响因子:0
- 作者:
Jason A. Castellanos;Nagaraj S. Nagathihalli;N. Merchant - 通讯作者:
N. Merchant
The Role of Myeloid Cells on the Development of Hepatic Metastases in Gastrointestinal Cancer
- DOI:
10.1016/j.gastha.2024.08.017 - 发表时间:
2025-01-01 - 期刊:
- 影响因子:
- 作者:
Austin R. Dosch;Mary P. Martos;Samara Singh;Karishma Kodia;Nipun B. Merchant;Nagaraj S. Nagathihalli - 通讯作者:
Nagaraj S. Nagathihalli
Nagaraj S. Nagathihalli的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Establishment of a method for evaluating automobile driving ability focusing on frontal lobe functions and its application to accident prediction
以额叶功能为中心的汽车驾驶能力评价方法的建立及其在事故预测中的应用
- 批准号:
20K07947 - 财政年份:2020
- 资助金额:
$ 32.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Evaluation of the Effectiveness of Multi-Professional Collaborative Assessment of Cognitive Function and Automobile Driving Skills and Comprehensive Support
认知功能与汽车驾驶技能多专业协同评估效果评价及综合支持
- 批准号:
17K19824 - 财政年份:2017
- 资助金额:
$ 32.48万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Development of Flexible Automobile Driving Interface for Disabled People
残疾人灵活汽车驾驶界面开发
- 批准号:
25330237 - 财政年份:2013
- 资助金额:
$ 32.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Automobile driving among older people with dementia: the effect of an intervention using a support manual for family caregivers
患有痴呆症的老年人的汽车驾驶:使用家庭护理人员支持手册进行干预的效果
- 批准号:
23591741 - 财政年份:2011
- 资助金额:
$ 32.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)